• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·033270.KS
Share

Korea United Pharm Inc. Stocks

₩ 17440Last Updated 24.07.2026

Issuer Rating

5/7
Performance

Strong

Risk

Moderate

Recommendation

Hold

Market Cap

₩ 170.10M

₩ 17440
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Korea United Pharm Inc. is a South Korean enterprise dedicated to the development, production, and distribution of a wide array of pharmaceutical products. The company's extensive portfolio encompasses therapeutic solutions for various medical fields, such as the respiratory, musculoskeletal, gastrointestinal, cardiovascular, and central nervous systems, in addition to treatments for cancer, infections, allergies, and immune disorders. It also supplies over-the-counter drugs. While deeply rooted in the South Korean market, the firm extends its reach internationally, exporting its medications to nearly 40 countries. Founded in 1987, Korea United Pharm Inc. is headquartered in Seoul, South Korea.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 033270.KS is 27000 and suggests 55.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation t

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.07.2026 08:00

AI Spending Threatens the Creditworthiness of Amazon, Meta, and Alphabet — Moody’s

25.07.2026 06:24

In July, four out of five of the short seller's bets from *The Short Game* paid off. Which ones?

25.07.2026 05:59

Nvidia and Palantir Urged the U.S. Not to Restrict "Open" AI Models Following China's Breakthrough

25.07.2026 05:03

SpaceX has successfully tested the Starship rocket for the first time since its IPO

25.07.2026 04:30

Paramount has put its merger with Warner Bros. on hold for nearly a year

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026